Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 6, 2015, Pages 663-669

  Moore, B K ^a   Anyalechi, E ^a   Van Der Walt, M ^b   Smith, S ^a   Erasmus, L ^c   Lancaster, J ^b   Morris, S ^a   Ndjeka, N ^d   Ershova, J ^a   Ismail, N ^c,e   Burton, D ^a   Menzies, H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^e UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cohort review; Drug resistance; Mycobacterium tuberculosis; Pediatric; South Africa

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILDHOOD MORTALITY; CLINICAL FEATURE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT OUTCOME; AGE DISTRIBUTION; CLINICAL TRIAL; CONTACT EXAMINATION; HIV INFECTIONS; MEDICAL RECORD; MIXED INFECTION; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; TIME; TRANSMISSION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; AGE DISTRIBUTION; AGE FACTORS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD; COINFECTION; CONTACT TRACING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAL RECORDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929408559     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0879     Document Type: Article

References (29)

1. World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Accessed February 2015.
2. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf. Accesed February 2015.
3. Jenkins H E, Tolman A W, Yuen C M, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014; 383: 1572-1579.
4. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013; 42: 701-707.
5. Dodd P, Gardiner E, Coghlan R, Seddon J. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health 2014; 2: 453-459.
6. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. WHO/HTM/TB/2014.03. Geneva, Switzerland: WHO, 2014.
7. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010; 50 (Suppl 3): S184-S194.
8. Ettehad D, Schaaf H, Seddon J, Cooke G, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
9. Schaaf H S, Marais B J, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis 2007; 7: 140.
10. Marais B J, Gie R P, Schaaf H S, Beyers N, Donald P R, Starke J R. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006; 173: 1078-1090.
11. Marais B J, Pai M. Recent advances in the diagnosis of childhood tuberculosis. Arch Dis Child 2007; 92: 446-452.
12. Schaaf H, Shean K, Donald P, et al. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003; 88: 1106-1111.
13. Seddon J, Hesseling A, Willemse M, Donald P, Schaaf H. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54: 157-166.
14. Schaaf H, Garcia-Prats A, Draper H, Hesseling A. Drug resistance surveillance in children with culture-confirmed tuberculosis in the Western Cape: a downward trend? 44th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), 2013; Paris, France, Int J Tuberc Lung Dis 2013; 17 (Suppl 2): S87. [OP-133-01].
15. Seddon J, Hesseling A C, Marais B J, Jordaan A, Victor T, Schaaf H S. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012; 16: 928-933.
16. Schaaf H, Hesseling A, Rautenbach C, Seddon J A. Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider epidemic? Int J Tuberc Lung Dis 2014; 18: 770-773.
17. Fairlie L, Beylis N C, Reubenson G, Moore D P, Madhi S A. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis 2011; 11: 28.
18. National Department of Health, Republic of South Africa. National tuberculosis management guidelines 2009. National Department of Health, Pretoria, Republic of South Africa, 2009.
19. National Department of Health. Tuberculosis strategic plan for South Africa, 2007-2011. Pretoria, South Africa, National Department of Health, 2006.
20. National Department of Health. Management of drug-resistant tuberculosis: policy guidelines. Pretoria, South Africa, National Department of Health, 2011.
21. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008. http://whqlibdoc.who.int/publications/2008/9789241547581-eng.pdf. Accessed February 2015.
22. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva Switzerland: WHO, 2011. Accessed February 2015.
23. Drobac P C, Mukherjee J S, Joseph J K, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022-2029.
24. Gegia M, Jenkins H E, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis 2013; 17: 624-629.
25. Marais E, Mlambo C K, Lewis J J, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection 2014; 42: 405-413.
26. World Health Organization. South Africa multidrug-resistant tuberculosis profile, 2011. Geneva, Switzerland: WHO, 2011. www.who.int/tb/data/profiles/en/ Accessed April 2011
27. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
28. World Health Organization. Roadmap for childhood tuberculosis: toward zero deaths. WHO/HTM/TB/2013.12. Geneva Switzerland: WHO, 2013. http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137-eng.pdf. Accessed February 2015.
29. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. WHO/HTM/TB/2013.16. Geneva, Switzerland: WHO, 2013. http://apps.who.int/iris/bitstream/10665/112472/1/9789241506335-eng.pdf. Accessed February 2015.